Asparaginase Erwinia chrysanthemi (recombinant)-rywn 20 mg/ML [Rylaze]
RxNorm 2561253

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2561253 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: asparaginase Erwinia chrysanthemi (recombinant)-rywn 20 mg/ML [Rylaze].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Asparaginase Erwinia chrysanthemi (recombinant)-rywn 20 mg/ML [Rylaze]
AUI:12651541
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Asparaginase Erwinia chrysanthemi (recombinant)-rywn 20 mg/ML [Rylaze]
(Atom ID: 12651541)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
asparaginase Erwinia chrysanthemi (recombinant)-rywn 20 MG/ML [Rylaze]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2561253
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12651541
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
2561253
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Asparaginase Erwinia chrysanthemi


Asparaginase Erwinia chrysanthemi is used with other chemotherapy medications to treat acute lymphocytic leukemia (ALL; a type of cancer of the white blood cells). It is used in patients who have had some types of allergic reactions to medications similar to asparaginase Erwinia chrysanthemi such as (asparaginase [Elspar] or pegaspargase [Oncaspar]). Asparaginase Erwinia chrysanthemi is an enzyme that interferes with natural substances necessary for cancer cell growth. It works by killing or stopping the growth of cancer cells.
[Learn More]


* Please review the disclaimer below.